Tina Verschuere

Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma

Abhishek D. Garg, Lien Vandenberk, Carolien Koks et al. · Science Translational Medicine · 2016 · 264 citations

Dendritic Cell, Adaptive Immune System, T Cell–driven Rejection +22

Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial

Hilko Ardon, Stefaan W. Van Gool, Tina Verschuere et al. · Cancer Immunology Immunotherapy · 2012 · 157 citations · Full text

Neuro-oncology, Cancer Immunosurveillance, Medicine +8

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

Martin J. van den Bent, Martin Klein, Marion Smits et al. · The Lancet Oncology · 2018 · 125 citations · Full text

Iii Glioma, Medicine, Metronomic Therapy +9

Glioma‐derived galectin‐1 regulates innate and adaptive antitumor immunity

Tina Verschuere, Jaan Toelen, Wim Maes et al. · International Journal of Cancer · 2013 · 84 citations · Full text

Dynamic stroma reorganization drives blood vessel dysmorphia during glioma growth

Thomas Mathivet, Claire Bouleti, Matthias Van Woensel et al. · EMBO Molecular Medicine · 2017 · 73 citations · Full text